Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bicalutamide Implant- Alessa Therapeutics

Next Previous
Search
Drug Profile

Bicalutamide Implant- Alessa Therapeutics

Alternative Names: Biolen - Alessa Therapeutics; Biolen bicalutamide implant - Alessa Therapeutics

Latest Information Update: 26 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alessa Therapeutics
  • Class Anilides; Antiandrogens; Antineoplastics; Fluorinated hydrocarbons; Nitriles; Small molecules; Tosyl compounds
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 03 May 2024 Efficacy and adverse events data from a phase I trial in Prostate cancer presented at the 119th Annual Meeting of the American Urological Association
  • 08 Sep 2023 Bicalutamide is still in phase-I development in Prostate-cancer in Australia (Implant) (NCT04284761)
  • 03 May 2023 Alessa Therapeutics completes phase-I trial in Prostate cancer in USA, New Zealand and Australia (Implant) (NCT04284761)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top